Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been created for PROMISE and PPP2 assessments (promise-pet.org).
Authors
- Sazan Rasul (ORCID: https://orcid.org/0000-0003-2898-3232)
- Anika Hüsing (ORCID: https://orcid.org/0000-0002-2685-9732)
- Lena M. Unterrainer
- Elin Trägårdh (ORCID: https://orcid.org/0000-0002-7116-303X)
- Matthias Miederer (ORCID: https://orcid.org/0000-0001-5075-5995)
- Tobias Hölscher (ORCID: https://orcid.org/0000-0002-9991-6152)
- Andrea Di Giorgio (ORCID: https://orcid.org/0000-0003-3981-1145)
- Anders Bjartell (ORCID: https://orcid.org/0000-0002-5761-3786)
- Claudia Kesch (ORCID: https://orcid.org/0000-0002-2656-2664)
- Jérémie Calais (ORCID: https://orcid.org/0000-0002-8839-4379)
- Ken Herrmann
- Michael Schäfers (ORCID: https://orcid.org/0000-0002-4008-2755)
- Laya Rahbar Nikoukar (ORCID: https://orcid.org/0000-0003-3213-8568)
- Andrei Gafita
- Kambiz Rahbar (ORCID: https://orcid.org/0000-0002-4591-4055)
- Karolien Goffin (ORCID: https://orcid.org/0000-0002-7453-0229)
- Matteo Bauckneht (ORCID: https://orcid.org/0000-0002-1937-9116)
- Francesco Lanfranchi (ORCID: https://orcid.org/0000-0002-6043-9627)
- Jonathan Miksch (ORCID: https://orcid.org/0000-0002-0121-0179)
- Felix Kind (ORCID: https://orcid.org/0000-0002-9398-5747)
- Sebastian Hoberück (ORCID: https://orcid.org/0000-0003-3601-0924)
- Adrien Holzgreve (ORCID: https://orcid.org/0000-0002-9566-8438)
- Gabriel T. Sheikh (ORCID: https://orcid.org/0000-0002-7026-9203)
- Isabel Rauscher (ORCID: https://orcid.org/0000-0003-4655-2153)
- Marcin Miszczyk (ORCID: https://orcid.org/0000-0002-4375-0827)
- Johannes Hüsing
- Wolfgang P. Fendler (ORCID: https://orcid.org/0000-0002-5106-3584)
- Michael S. Hofman (ORCID: https://orcid.org/0000-0001-8622-159X)
- Martin Stuschke (ORCID: https://orcid.org/0000-0001-6836-0940)
- Thomas A. Hope (ORCID: https://orcid.org/0000-0002-2228-5823)
- Timo Soeterik (ORCID: https://orcid.org/0000-0002-0259-8750)
- Boris Hadaschik (ORCID: https://orcid.org/0000-0002-1052-2692)
- Martin Bögemann (ORCID: https://orcid.org/0000-0002-2569-4446)
- Andrea Farolfi (ORCID: https://orcid.org/0000-0002-5443-4301)
- Christian H. Pfob (ORCID: https://orcid.org/0000-0003-2989-5883)
- Matthias J. Eiber (ORCID: https://orcid.org/0000-0003-2654-6872)
- Madeleine J. Karpinski
Institutions
- Johns Hopkins University (US)
- University of Freiburg (DE)
- University of Augsburg (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Johns Hopkins Medicine (US)
- Peter MacCallum Cancer Centre (AU)
- University Medical Center Freiburg (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- University Hospital Heidelberg (DE)
- TUM Klinikum (DE)
- University of California System (US)
- LMU Klinikum (DE)
- Institut für Medizinische Informatik, Biometrie und Epidemiologie (DE)
- Comprehensive Cancer Center Vienna (AT)
- St. Antonius Ziekenhuis (NL)
- University Hospital Münster (DE)
- National Center for Tumor Diseases (DE)
- Azienda USL di Bologna (IT)
- Essen University Hospital (DE)
- National Cancer Registry (IE)
- Skåne University Hospital (SE)
- Ospedale Policlinico San Martino (IT)
- University Hospital Ulm (DE)
- Molecular Theranostics (United States) (US)
- University Hospital Carl Gustav Carus (DE)
- University of Duisburg-Essen (DE)
- Medical University of Vienna (AT)
- Ludwig-Maximilians-Universität München (DE)
- University of Genoa (IT)
- University of Bologna (IT)
- KU Leuven (BE)
Publication Details
- Journal
- European Urology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1016/j.eururo.2025.04.017
- Citations
- 22
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 33.40
Funders
- Prostate Cancer Foundation
- Prostate Cancer Research & Education Foundation
- AstraZeneca
- Universitätsklinikum Essen
- Innovative Health Initiative
- Deutsche Forschungsgemeinschaft
- Narodowa Agencja Wymiany Akademickiej
- Agencja Badań Medycznych